Learn more about our unprecedented approach,
from problem to our solution.
is the most common and aggressive malignant primary brain tumour.
40,000 new cases per year globally
GBM tumours are difficult to treat
Nearly 100% of patients experience disease relapse after initial treatment
is of limited benefit and prognosis is poor
Surgery, chemotherapy and Radiotherapy
There are 4 approved therapies which have had minimal impact on survival – TMZ the only therapy to demonstrate OS benefit (2.5 months)
Average survival after diagnosis is 15 months
A platform technology leveraging neurobiology of brain stem cells to discover biological drugs that differentiate tumor cells,
particularly aggressive cancer stem cells.
An unprecedented approach in the field of solid tissue cancers
responsible for repeated failures in neurocology
Pipeline of unconventional & innovative leads
Defines new leads for differentiation, invasion, apoptosis, checkpoint inhibitors
Differential Display Data Integration
Our Platform is based on the largest collection of brain primary cancer and normal stem cell lines.
By proprietary assays it discovers and validates new leads that tackle specific cell functions in cancer-initiating cells with unprecedented, unmatched prediction ability